Gram Negative Mutants Resistant to 4-Quinolones: Are they Competent Pathogens?

Abstract

Nalidixic acid, the archetypal 4-quinolone antibacterial agent, was limited in its use by a reputation for the ease of development of resistance both in vitro and in vivo (Ronald et al. 1966). The ease with which even the most inexperienced investigators can isolate spontaneous mutants resistant to therapeutic levels of the drug in the laboratory merely serves to reinforce this reputation and colours our perception of possible problems to come with the new generations of 4-quinolones.